Pegaptanib sodium: Treatment of age-related macular degeneration treatment of diabetic retinopathy anti-VEGF aptamer

Drugs of the Future

Volumn 27, Issue 9, 2002, Pages 841-845

  Sorbera, L A ^a   Leeson, P A ^a   Bayes M ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PEGAPTANIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; ARTICLE; DIABETES MELLITUS; DIABETIC RETINOPATHY; EYE PAIN; FATIGUE; HUMAN; LASER COAGULATION; NONHUMAN; PHOTOTHERAPY; RECURRENT DISEASE; RETINA MACULA AGE RELATED DEGENERATION; SCOTOMA; SUBRETINAL NEOVASCULARIZATION; VISUAL DISORDER; VISUAL IMPAIRMENT;

EID: 0036760251     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2002.027.09.695013     Document Type: Article

References (26)

1. Hyman, L. Epidemiology of eye disease in the elderly. Eye 1987, 1: 330-41.
2. Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1990, 108: 816-24.
3. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol 1991, 109: 1109-14.
4. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991, 109: 1220-31.
5. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials - TAP report. Arch Ophthalmol 1999, 117: 1329-45.
6. Ferrara, N., Houck, K., Jakeman, L., Leung, D.W. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992, 13: 18-32.
7. Leung, D.W., Cachianes, G., Kuang, W.J., Goeddel, D.V., Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246: 1306-9.
8. Carmeliet, P., Ferreira, V., Breier, G. et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996, 380: 435-9.
9. Kim, K.J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H.S., Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362: 841-4.
10. Amano, S., Rohan, R., Kuroki, M., Tolentino, M., Adamis, A.P. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1998, 39: 18-22.
11. Adamis, A.P., Shima, D.T., Tolentino, M.J., Gragoudas, E.S., Ferrara, N., Folkman, J., D'Amore, P.A., Miller, J.W. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996, 114: 66-71.
12. Aiello, L.P., Pierce, E.A., Foley, E.D., Takagi, H., Chen, H., Riddle, L., Ferrara, N., King, G.L., Smith, L.E. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Rci USA 1995, 92: 10457-61.
13. Adamis, A.P., Miller, J.W., Bernal, M.T., D'Amico, D.J., Folkman, J., Yeo, T.K., Yeo, K.T. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994, 118: 445-50.
14. Aiello, L.P., Avery, R.L., Arrigg, P.G. et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New Engl J Med 1994, 331: 1480-7.
15. Smith, L.E., Wesolowski, E., McLellan, A., Kostyk, S.K., D'Amato, R., Sullivan, R., D'Amore, P.A. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994, 35: 101-11.
16. Tuerk, C., Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249: 505-10.
17. Ellington, A.D., Szostak, J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346: 818-22.
18. 165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 1998, 273: 20556-67.
19. 165-mediated cellular responses in vitro. In Vitro Cell Dev Biol Anim 1999, 35: 533-42.
20. The Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina - J Retin Vitr Dis 2002, 22: 143-52.
21. Tomkinson, B., Bendele, R., Bill, J., Bridonneau, P., Brown, E., Janjic, N., LeRay, S.G.J., Emerson, D. NX1838, a VEGF-specific antagonist aptamer, inhibits the growth of human xenografts in nude mice and enhances a suboptimal dose of Taxol. Proc Am Assoc Cancer Res 1999, 40: Abst 4097.
22. Carrasquillo, K.G., Ricker, J., Rigas, I.K., Adamis, A.P. Controlled delivery of anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid. Annu Meet Assoc Res Vision Ophthalmol (May 5-10, Fort Lauderdale) 2002, Abst 2324.
23. Tucker, C.E., Chen, L.-S., Judkins, M.B., Farmer, J.A., Gill, S.C., Drolet, D.W. Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. J Chromatogr B - Biomed Sci Appl 1999, 732: 203-12.
24. Drolet, D.W., Nelson, J., Tucker, C.E. et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res 2000, 17: 1503-10.
25. Mones, J. Anti-VEGF therapy for patients with exudative age-related macular degeneration: Results of phase I and II clinical trials. 4th Int Symp Ocular Pharmacol Pharm (Feb 28-March 3, Seville) 2002, 27.
26. Eye Tech completes enrollment in two pivotal Macugen trials. DailyDrugNews.com (Daily Essentials) August 12, 2002.